Journal of medicinal chemistry p. 31 - 37 (1978)
Update date:2022-08-16
Topics:
Kupchan
Sneden
Branfman
Howie
Rebhun
McIvor
Wang
Schnaitman
In an effort to determine the structural requirements for the significant antileukemic, cytotoxic, antitubulin, and antimitotic activity exhibited by the novel ansa macrolide, maytansine (1), four new C-3 ester and six new C-9 ether homologues were synthesized. The biological activities of these compounds were assayed and compared to the activities of previously reported, naturally occurring maytansinoids. From the data, it is apparent that presence of the C-3 ester is necessary for significant activity, and variations in the ester group are not accompanied by marked changes in activity. However, elimination of the ester group, as in maytansinol (7), maysine (8), normaysine (9), and maysenine (10), results in a significant decrease in biological activity. Blockage of the C-9 carbinolamide via etherification markedly reduces antileukemic and cytotoxic activity and slightly reduces antitubulin activity but has relatively little effect on antimitotic activity against sea urchin eggs. Thus, a free carbinolamide at C-9 is advantageous for optimal activity.
View MoreSuzhou Kangrun Pharmaceutical, Inc
Contact:86-512-63912376,63913329
Address:Building 2, No. 2358 ,Chang'an Rd, Wujiang Economic Development Zone Pioneering park, china
Wuhan Shangrisyn chemicals Technology Co.,Ltd(expird)
Contact:+86-027-84466317 __ +86-15387123698
Address:wuhan - china
Disynthesis Chemical Technology Co. Ltd.
Contact:+86-571-88194596
Address:Dengyun road 380, Gongshu district, Hangzhou city, China
Jiangxi Province Bethel Pharmaceutical Co., Ltd.
Contact:+86-795-259 3456 ,+86-15957688008 13566650571
Address:Huangjindui Chemical Park, Shanggao County ,Yichun city,Jiangxi Province
Contact:13120882795;+86-21-34621078;+86-021-31122318
Address:Suite 2,No.2715 Longwu Road
Doi:10.1021/jo00314a057
(1981)Doi:10.1016/j.ejmech.2020.112253
(2020)Doi:10.1007/s00706-005-0421-9
(2006)Doi:10.1007/s11172-016-1642-2
(2016)Doi:10.1002/ejoc.201601549
(2017)Doi:10.1039/c8dt03056a
(2018)